scv-07

Golotimod hydrochloride (SCV 07 hydrochloride) is an immunomodulating peptide with antimicrobial properties. It enhances antituberculosis therapy effectiveness, promotes thymic and splenic cell proliferation, and boosts macrophage functionality. Furthermore, it inhibits STAT3 signaling, thereby modifying the duration and intensity of oral mucositis in animal models subjected to radiation or a combination of radiation and Cisplatin. Additionally, Golotimod hydrochloride has shown potential as a treatment for recurrent genital herpes simplex virus type 2 (HSV-2) [1] [2] [3].

Golotimod (SCV 07) is an antimicrobial dipeptide with immunomodulatory activity that significantly improves the efficacy of anti-tuberculosis therapy, induces thymic and splenic cell proliferation, modulates macrophage function, and inhibits STAT3 signaling.Golotimod has been used in the study of recurrent genital Herpes Simplex Virus 2 (HSV-2) infection and oral mucositis.

Golotimod TFA (SCV 07 TFA) is an immunomodulatory peptide with antibacterial properties that significantly increases the effectiveness of anti-tuberculosis studies, stimulates thymus and splenocyte proliferation and improves macrophage function. Golotimod TFA has the potential to be used in studies of recurrent genital herpes simplex virus type 2 (HSV-2).